Rise and shine, another busy day is on the way. And here on the Pharmalot campus, where clouds are hovering and leaves are falling, we are coping with our mandatory cup of stimulation. Our to-do list is so crammed, in fact, that posting may be sporadic over the next day or two as we complete some more involved efforts than usual. Meanwhile, here is the usual, although lengthy, items of interest. Hope you have a successful day and do keep in touch…
US prosecutors plan to ask the Canadian and British governments to extradite officials with an online pharmacy on charges of smuggling $78 million worth of mislabeled, unapproved and counterfeit cancer drugs into the country; Federal prosecutors in at least four states are mounting investigations into what they describe as widespread fraud by compounding pharmacies in claims to the Tricare health-insurance program; Mallinckrodt stock plummeted by more than 25 percent yesterday after Andrew Left of Citron Research, the short seller, tweeted the drug maker has “more downside” than Valeant Pharmaceuticals; A jury ordered Johnson & Johnson to pay $1.8 million to a Maryland man who developed female breasts while taking the company’s Risperdal antipsychotic drug; an Indian government official says that complaints about quality issues at Indian drug makers are part of a “turf war” with Western companies.
